Zhang C, Shen L, Zhu Y, Xu R, Deng Z, Liu X, Ding Y, Wang C, Shi Y, Bei L, Wei D, Thorne RF, Zhang XD, Yu L, Chen S (2021) KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia. Theranostics 11(6):2691-2705. doi: 10.7150/thno.50571
Objective: To identify histone lysine demethylases (KDMs) with altered expression in chronic myelogenous leukemia (CML) and define their contribution to imatinib resistance.
Summary: KDM6A promotes imatinib-resistance in CML cells. The identification of the KDM6A/YY1/TRKA axis as a novel imatinib-resistance mechanism represents an unexplored avenue to overcome tyrosine kinase inhibitor resistance in CML.
Usage: Western blot
Related Products: trkA Rabbit Polyclonal (Cat. #AB-N03)